gp209-2m antigen
Biologicalexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 1998 (NCT00019487)
Timeline
Indications
Studied for
Mechanism of action
- Melanocyte protein PMELImmunity, active
PMEL immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- gp209-2m antigen
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00005633 | Phase 1 | Jun 1, 1999 | Cornell University, National Cancer Institute (NCI) |
| NCT00019487 | Phase 2 | Nov 1, 1998 | National Cancer Institute (NCI), National Institutes of Health (NIH) |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 2 | 1 | 2 | 1998 |
| Cornell University | Academic/Hospital | 1 | 1 | 1 | 1999 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 1998 |
3 organizations
Page 1 / 1